Szczygielski Orest, Dąbrowska Emilia, Niemyjska Sylwia, Przylipiak Andrzej, Zajkowska Monika
Clinic of Paediatric Surgery, Institute of Mother and Child, Kasprzaka Str 17a, 01-211 Warsaw, Poland.
General Hospital in Wysokie Mazowieckie, Szpitalna Str 5, 18-200 Wysokie Mazowieckie, Poland.
Int J Mol Sci. 2024 Dec 18;25(24):13558. doi: 10.3390/ijms252413558.
Malignant melanoma is one of the most important dermatological neoplasms. The high mortality rate associated with this skin disease is primarily due to the occurrence of metastases, while the diagnosis and treatment of melanoma in its early stages has a favorable prognosis. Early detection is crucial because the success of treatment is directly related to the depth of cancerous growth. The family of matrix metalloproteinases (MMPs) plays a critical role in the initiation and progression of melanoma. Prominent MMPs, including MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, and MMP-14, have been shown to significantly contribute to the development of melanoma. The tumor microenvironment, particularly the extracellular matrix (ECM), has emerged as a critical factor in modulating cancer progression. This review focuses on the role of matrix metalloproteinases and their inhibitors in ECM degradation and the subsequent progression of melanoma, as well as their potential as therapeutic targets.
恶性黑色素瘤是最重要的皮肤肿瘤之一。与这种皮肤疾病相关的高死亡率主要是由于转移的发生，而黑色素瘤在早期阶段的诊断和治疗预后良好。早期检测至关重要，因为治疗的成功与癌性生长的深度直接相关。基质金属蛋白酶（MMPs）家族在黑色素瘤的发生和发展中起关键作用。包括MMP-1、MMP-2、MMP-3、MMP-9、MMP-13和MMP-14在内的重要MMPs已被证明对黑色素瘤的发展有显著贡献。肿瘤微环境，特别是细胞外基质（ECM），已成为调节癌症进展的关键因素。本综述重点关注基质金属蛋白酶及其抑制剂在ECM降解以及随后黑色素瘤进展中的作用，以及它们作为治疗靶点的潜力。
